Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biothree OD
- Development stage
- Unknown
- Lead developer
- TOA Biopharma
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Biothree OD is an orally disintegrating probiotic tablet developed by TOA BIOPHARMA, containing a synergistic combination of three live bacterial strains: *Enterococcus faecalis* T-110, *Clostridium butyricum* TO-A, and *Bacillus mesentericus* TO-A. This symbiotic formulation is designed to restore and maintain a healthy intestinal microbiota. The mechanism involves *B. mesentericus* and *E. faecalis* supporting the growth of *C. butyricum*, which produces butyric acid—a short-chain fatty acid that provides energy to colonocytes, maintains the intestinal barrier, and stimulates bowel motility. The OD (orally disintegrating) technology allows the tablet to dissolve quickly in the mouth, facilitating use in elderly patients with chronic constipation or individuals with swallowing difficulties. It is marketed in Japan for the treatment of constipation, diarrhea, and abdominal bloating associated with intestinal dysbiosis.
- Brand names
- Biothree ODBio-Three OD
- Other names
- Bio-ThreeBiothree
Beyond the preview
Go deeper on Biothree OD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biothree OD.